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78-kDa glucose-regulated protein (GRP78) is 
over-expressed in human breast carcinomas. GRP78 
expression was studied in 40 spontaneous canine mam-
mary tumors and evaluated in relation to tumor histo-
logical type, mode of growth, grade, lymph node me-
tastases and distant metastases. All tumors exhibited 
GRP78 immunostaining. In the normal canine mam-
mary gland, GRP78 was also expressed although not in 
all cases. In carcinomas GRP78 was detected in the 
cytoplasm in more than 50% of tumor cells in the vast 
majority of cases (87.5%). There was a significant as-
sociation between the absence of squamous differentia-
tion (P = 0.02) and GRP78 over-expression, but no 
association with other clinico-pathological features. 
GRP78 was often co-expressed with galectin-3 in ca-
nine mammary tumors (CMT). 
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GRP78 expression in canine mammary tumors: association with malignancy 
The microenvironment of solid tumors possesses sev-
eral stressful conditions such as hypoxia, low pH, and 
glucose deprivation (Delie et al. 2012, Li et al. 2012). 
These conditions induce tumor cells to express a fami-
ly of proteins which trigger protective mechanisms 
(Fernandez et al. 2000, Lee 1992, Li & Li 2012), the 
heat shock proteins (HSPs) and glucose-regulated pro-
teins (GRPs) (Fernandez et al. 2000, Prabhu et al. 
2012). The best characterized GRP is the GRP78, also 
known as the immunoglobulin heavy chain binding 
protein (BiP). GRP78 is a chaperon protein present in 
the lumen of endoplasmatic reticulum (ER) where it 
plays an important role in cancer progression, malig-
nancy and drug resistance (Delie et al. 2012, Li & Li 
2012, Wang et al. 2009). Galectin-3 is a member of the 
galectins family of beta-galactosides recognizing lec-
tins (Cummings et al. 2009). It has several roles in 
cancer progression, including an anti-apoptotic activity 
in response to microenvironment stressors (Lee 2007, 
Wang et al. 2009).  
 Canine mammary tumors (CMT) are the most 
frequent type of canine neoplasia accounting for ap-
proximately 25–50% of cases and 40–50% are malig-
nant (de Oliveira et al. 2010). These spontaneously 
occurring tumors often metastasize and are thus con-
sidered a good model to study the process. This com-
pared oncobiology approach has the potential to bene-
fit both dogs and human breast cancer patients 
(Paoloni et al. 2008).  
 The present study aimed to assess GRP78 ex-
pression in benign and malignant CMT using immuno-
histochemistry; to determine whether it is associated 
with the clinicopathological features of CMT; and fi-
nally, to assess GRP78 co-expression with galectin-3 
by immunofluorescence. The series of CMT was ob-
tained from the Pathology Department archives of IC-
BAS-University of Porto. Briefly, formalin-fixed, par-
affin-embedded H&E-stained sections examined by 
three pathologists, and classified according to the 
WHO classification for tumours in domestic animals, 
were used to assess GRP78 expression.  Briefly, 4-μm-
thick paraffin sections were deparaffinized, hydrated, 
and H2O2 was used to block endogenous peroxidase 
activity. After blocking, sections were incubated with 
rabbit anti-GRP78 (Santa Cruz Biotechnology, CA), 
overnight at 4°C. Incubation with a biotin conjugated 
swine anti-rabbit secondary antibody followed by the 
avidin–biotin–peroxidase complex during 30 minutes 
(Vector Laboratories) was performed. Diaminobenzi-
dine tetrahydroxychloride solution (DAB, Dako) was 
used to reveal peroxidase activity and finally, sections 
were counterstained with hematoxylin. Results were 
analyzed using SPSS software (version 13.0). Associa-
tion hypotheses were tested, using Fisher’s exact test 
or Chi-square test for discrete variables. For simultane-
ous visualization of GRP78 and galectin-3 sections 
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were incubated with the primary antibodies rat anti-
galectin-3 (Bioscience, CA) and rabbit anti-GRP78 
(Santa Cruz Biotechnology, CA) for 1 hour at room 
temperature. Then, upon washing, sections were incu-
bated with Alexa 588-conjugated donkey anti-rat and 
Alexa 594-conjugated rabbit anti-goat secondary anti-
bodies (Invitrogen) for 45 minutes. All sections were 
incubated with 4’-6-Diamidino-2-phenylindole (DAPI) 
for 15 minutes and mounted in glycerol-based Vec-
tashield medium (Vector, Burlingame, CA). Slides 
were analyzed under a Zeiss fluorescence microscope. 
Tumors were grouped, according to the percentage of 
GRP78 immunoreactive cells, into: <25%; 25–50%; 50
–75%, or >75% stained tumor cells.  Malignant CMT 
(40 cases) and benign CMT (5 cases) were used in the 
present study. Malignant CMT were classified accord-
ing to the histological types, size, distant and 
lymph node metastases and squamous differ-
entiation.  
 All tumors expressed GRP78, alt-
hough expression levels differed between 
cases. The vast majority of malignant tumors 
presented GRP78 expression in more than 
50% of tumor cells in 35 out of 40 cases 
(87.5%). Indeed, 18 out of 40 (45%) of ma-
lignant CMT cases presented GRP78 stain-
ing in more than 75% of tumor cells (Figure 
1A). In striking contrast, there were no be-
nign CMT with more than 75% stained cells 
(Figure 1A). Interestingly, the normal tissue 
adjacent to benign CMT also presented low-
er expression of GRP78 than that adjacent to 
malignant CMT as in the tumor itself 
(Figure 1B). Clinico-pathological features of 
tumors, as well as associations with GRP78 
expression, are summarized in Table 1. No 
statistically significant associations were 
found in histological type, mode of growth, 
necrosis, lymph node metastases or distant 
metastases (p>0.05). However GRP78 pre-
sented a significant association with squa-
mous differentiation (p=0.02). GRP78 was 
frequently co-expressed with galectin-3 in 
CMT both in the periphery and in invasive 
front of malignant CMT (Figure 2). Tumor 
microenvironment induces physiologic en-
doplasmic reticulum stress, and the UPR 
(unfolded protein response) is essential for 
survival of tumor cells subjected to persis-
tent hypoxia (Lee et al. 2006). The chaper-
one protein GRP78 is a master UPR regula-
tor, aberrantly expressed in a variety of hu-
man cancers (Prabhu et al. 2012). In our 
study both benign and malignant CMT ex-
pressed GRP78. However, GRP78 expres-
sion is higher in malignant when compared 
to benign tumors. Our results are in agree-
ment with Fernandez et al. (2000), who 
showed that the levels of both GRP78 
mRNA and protein in human breast cancer 
were increased in the malignant tumors 
when compared to the benign tumors and 
normal tissues. GRP78 expression is highly 
elevated in different cancer cell lines, solid 
tumors, and human cancer biopsies, being 
frequently related to malignancy and metas-
tasis (Wang et al. 2009). Since GRP78/BIP 
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Figure 1. GRP78 is up regulated in malignant CMT. (A) GRP78 immuno-
histochemical staining was analyzed in a series malignant and benign 
CMTs, and tumors were compared according to the percentage of GRP78 
expressing tumor cells. (B) Representative photomicrographs depict 
GRP78 immunostaining (brown color) with hematoxilin counterstain in 
malignant and benign CMT. GRP78 expression in CMTs was accessed by 
immunohistochemistry using the modified avidin–biotin–peroxidase com-
plex method (de Oliveira et al. 2011), with an anti-GRP78 antibody (1:50; 
Santa Cruz Biotechnology). Peroxidase activity was examined using dia-
minobenzidine tetrahydroxychloride solution (DAB, Dako) as the sub-
strate.  
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Table 1. Association between clinico-pathological features of tumors and GRP78 expression.  
1 Forty CMT were randomly selected from the files of the Veterinary Pathology Department of ICBAS-UP. Histological exami-
nation was performed independently by two pathologists and tumors were classified according to WHO criteria (Misdorp et al., 
1999). 
2 Immunohystochemestry studies were performed and the tumors were grouped into <25%; 25–50%; 50–75%, or >75% stained 
tumor cells according to the percentage of GRP78 immunoreactive cells.  
3 SPSS software (version 13.0) was used for statistical analysis, applying Fisher’s exact or χ2 tests. Samples were scored accord-
ing to the percentage of GRP78 positive cells. 
is induced under adverse conditions for cell survival, 
such as tumor microenvironment, acting as an inhibitor 
of stress-induced apoptosis it is feasible to think that it 
might be up-regulated in malignancy. High expression 
of GRP78 is related to the cells’ exposure to stress 
such as hypoxia and glucose deprivation, which in turn 
are associated with more aggressive tumor behavior 
(Lee 2001). To the best of our knowledge, this is the 
first study of GRP78 expression in CMT.  
 There was no significant association between 
tumor clinicopathological features and GRP78 expres-
sion. Both benign and malignant CMTs express 
GRP78 in adjacent mammary glands which is in agree-
ment with a recent study which denotes that GRP78 
expression are related with 
mammary gland development 
(Zhu et al. 2014). The fact 
that normal mammary glands 
adjacent to malignant lesions 
present more GRP78 than 
those observed in benign cas-
es reinforces a role for pro-
gression towards malignancy 
and its related microenviron-
ment in up-regulating GRP78 
expression. Previous studies 
show that GRP78 is essential 
for human tumor progression 
due to its roles played in sev-
eral processes such as prolif-
eration, apoptosis inhibition, 
angiogenesis promotion and 
genomic instability (Jamora 
et al. 1996, Li & Li 2012, 
Wang et al. 2009). GRP78 is 
involved in the regulation of 
invasion in cancer by modu-
lated FAK and JNK signaling 
pathways (Yuan et al. 2015). 
GRP78 also promotes tumor 
aggressiveness by enhancing 
AKT signaling and also pro-
tects the tumor cells from 
apoptosis, enabling them to 
continue to proliferate. 
Among other mechanisms, 
GRP78 over-expression 
blocks BIK-induced apopto-
sis, suppressed estrogen star-
vation-induced BAX activa-
tion, hindering mitochondrial 
permeability transition and, 
consequently, apoptosis 
(Zhou et al. 2011).  Regard-
ing apoptosis suppression, 
our present data points to a 
combined expression of 
GRP78 and anti-apoptotic 
galectin-3. Further studies are 
warranted in order to ascer-
tain if there is any common 
link in the regulation of these 
two proteins during mamma-
ry tumor progression. As ga-
lectin-3, GRP78 can also ele-
vate the number of inflamma-
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Figure 2. GRP78 co-express with galectin-3 in malignant cells. Co-expression between 
galectin-3 (green color) and GRP78 (red color) was assessed by double-labeling immuno-
fluorescence. Sections were incubated with the first primary antibodies rat anti-galectin-3 
(Bioscience) 1:200 in 5% bovine serum albumin (BSA) and rabbit anti-GRP78 (Santa 
Cruz Biotechnology) 1:50 for 1 hour at room temperature they were then washed in PBS 
and incubated with Alexa 588-conjugated with a donkey anti-rat (1:200) and Alexa 594-
conjugated with a rabbit anti-goat antibody (1:200) (Invitrogen) respectively for 45 min. 
All sections were then incubated with 1:100 PBS diluted 4’-6-Diamidino-2-phenylindole 
(DAPI) for 15 min and mounted in glycerol-based Vectashield medium (Vector, Burlin-
game, CA). Slides were analyzed with a Zeiss fluorescent microscope. Co-expression 
(yelow color) was observed both in cells in tumor periphery (A) and in specific cells with-
in the tumor (B). Scale bar in lower right image represents 50μM. 
 
tory cells that are important for the neoplastic process 
(Fortuna-Costa et al. 2014, Li & Li 2012). Despite a 
previous study where no differences were observed 
between squamous differentiation and mRNA expres-
sion levels of GRP78 in non-small cell lung cancer 
tissues (Sun et al. 2012), our results found an associa-
tion between GRP78 expression and absence of squa-
mous differentiation. Another previous study described 
that no correlation exists between good prognosis and 
patients with bladder cancer which present squamous 
differentiation (Antunes et al. 2007). 
 In conclusion, differing levels of GRP78 ex-
pression are present in benign and malignant CMT 
tissues. Our data points to an important role for GRP78 
in the malignant phenotype in canine mammary carcin-
ogenesis. Furthermore, this seems to be associated to 
galectin-3 in this neoplastic context. 
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